Sign inJoin waitlistJoin the waitlist

Jan Kemnade

Associate Program Director and Leader of Evidence Based Medicine Instruction · Mobile Infirmary Medical Center

Credentials: · · · · · · · · · ·

History

and of Evidence Based Medicine Instruction · Mobile Infirmary Medical Center
Present
UAB Department of Medicine, Division of Hematology-Oncology
Present
Thomas Hospital
Present

Hematology and Medical Oncology
Baylor College of Medicine
2016–2019
Internal Medicine
Thomas Hospital
2016–2019
Baylor College of Medicine
2009–2013
Baylor College
2012

Research

Metformin generates profound alterations in systemic and tumor immunity with associated antitumor effects
Journal for ImmunoTherapy of Cancer · 2021 · 53 citations
Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients
Cancer · 2017 · 39 citations
Persistent ethnicity-associated disparity in anti-tumor effectiveness of immune checkpoint inhibitors despite equal access
Cancer Research Communications · 2022 · 33 citations

Vlad Sandulache
9 papers
DH
David Hernandez
5 papers
Andrew Sikora
4 papers
AS
Anita Sabichi
4 papers
AH
Andrew Huang
3 papers
Heath Skinner
3 papers
Courtney Miller-Chism
2 papers
DW
David Wilde
2 papers · 2 as a resident
Marcus Florez
2 papers
QH
Quillan Huang
2 papers
SL
Syeling Lai
2 papers
Wendong Yu
2 papers

Clinical trials

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Site PI · Recruiting · Phase 2, Phase 3
SWOG Cancer Research Network
2025–2028
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2032
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2024–2028
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2023–2028